Overview

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.
Phase:
Phase 3
Details
Lead Sponsor:
Prothena Biosciences Ltd.